Sir Colin Terence Dollery (14 March 1931 – 12 December 2020) was a clinical pharmacologist who spent much of his life working for SmithKline Beecham and its successor, Glaxo Smith Kline.
[5] After graduating in medicine from the University of Birmingham in 1956, Dollery specialized in clinical pharmacology.
He was appointed as a lecturer in therapeutics at the Royal Postgraduate Medical School, London, in 1963 and was promoted to Professor of Clinical Pharmacology in 1968.
Dollery spent time in both academia and industry (SmithKline Beecham and then GSK post the merger).
He was also active within IUPHAR, where he was part of the clinical translational pharmacology group of the Nomenclature Committee.